Loading

SCIENCE

  • by Paul Armentano, NORML Deputy Director June 28, 2017

    medical_mj_shelfPain patients report successfully substituting cannabis for opioids and other analgesics, according to data published online in the journal Cannabis and Cannabinoid Research.

    Researchers from the University of California, Berkeley and Kent State University in Ohio assessed survey data from a cohort of 2,897 self-identified medical cannabis patients.

    Among those who acknowledged having used opioid-based pain medication within the past six months, 97 percent agreed that they were able to decrease their opiate intake with cannabis. Moreover, 92 percent of respondents said that cannabis possessed fewer adverse side-effects than opioids. Eighty percent of respondents said that the use of medical cannabis alone provided greater symptom management than did their use of opioids.

    Among those respondents who acknowledged having recently taken nonopioid-based pain medications, 96 percent said that having access to cannabis reduced their conventional drug intake. Ninety-two percent of these respondents opined that medical cannabis was more effective at treating their condition than traditional analgesics.

    Authors concluded: “[M]ore people are looking at cannabis as a viable treatment for everyday ailments such as muscle soreness and inflammation. … [T]his study can conclude that medical cannabis patients report successfully using cannabis along with or as a substitute for opioid-based pain medication.”

    The study’s conclusions are similar to those of several others, such as these herehereherehere, and here, finding reduced prescription drug use and spending by those with access to cannabis. Separate studies report an association between cannabis access and lower rates of opioid-related abuse, hospitalizations, traffic fatalities, and overdose deaths.

    Full text of the study, “Cannabis as substitute for opioid-based pain medication: patient self-report,” appears online here.

  • by Paul Armentano, NORML Deputy Director June 22, 2017

    thumbs_upThe enactment of statewide laws regulating the adult use and sale of cannabis is not associated with subsequent changes in traffic fatality rates, according to an analysis of traffic safety data (“Crash fatality rates after recreational marijuana legalization in Washington and Colorado”) published today in the American Journal of Public Health.

    Investigators from the University of Texas-Austin evaluated crash fatality rates in Colorado and Washington pre- and post-legalization. They compared these rates to those of eight control states that had not enacted any significant changes in their marijuana laws.

    “We found no significant association between recreational marijuana legalization in Washington and Colorado and subsequent changes in motor vehicle fatality rates in the first three years after recreational marijuana legalization,” author concluded.

    They further reported, “[W]e also found no association between recreational marijuana legalization and total crash rates when analyzing available state-reported nonfatal crash statistics.”

    Commenting on the findings, NORML Deputy Director Paul Armentano said: “These conclusions ought to be reassuring to lawmakers and those in the public who have concerns that regulating adult marijuana use may inadvertently jeopardize public safety. These results indicate that such fears have not come to fruition, and that such concerns ought not to unduly influence legislators or voters in other jurisdictions that are considering legalizing cannabis.”

    A prior study published last year by the same journal reported that the enactment of medical marijuana legalization laws is associated with a reduction in traffic fatalities compared to other states, particularly among younger drivers.

    Fatal accident rates have fallen significantly over the past two decades — during the same time that a majority of US states have legalized marijuana for either medical or social use. In 1996, the US National Highway Traffic Safety Administration reported that there were an estimated 37,500 fatal car crashes on US roadways. This total fell to under 30,000 by 2014.

    A summary of the study appears online under ‘First Look’ on the apha.org website here.

  • by Paul Armentano, NORML Deputy Director June 20, 2017

    oil_bottlesOral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.

    Investigators from the University of Nottingham in the United Kingdom assessed the effects of a single oral dose of 600 mg of CBD extract versus placebo in nine male subjects.

    Cannabidiol administration reduced resting systolic blood pressure and stroke volume (the amount of blood pumped by the left ventricle of the heart in one contraction). Compared to placebo, CBD intake was associated with reduced BP levels following exercise and in response to stress. Increased heart rate was observed following CBD administration, but no “adverse events” were reported by participants either during or following the study sessions.

    Authors concluded: “Our data show that a single dose of CBD reduces resting blood pressure and the blood pressure response to stress, particularly cold stress, and especially in the post-test periods. This may reflect the anxiolytic and analgesic effects of CBD, as well as any potential direct cardiovascular effects. … Further research is also required to establish whether CBD has any role in the treatment of cardiovascular disorders such as a hypertension.”

    Full text of the study, “A single dose of cannabisiol reduces blood pressure in healthy volunteers in a randomized crossover study,” is online here.

  • by Paul Armentano, NORML Deputy Director June 13, 2017

    no_marijuanaThe enactment of medical marijuana laws is not associated with increased rates of problematic cannabis use, according to data published online in the journal Addiction.

    Columbia University investigators assessed cannabis use trends in states in the years following the passage of medicalization. They reported “no significant change in the prevalence of past-month marijuana use among adolescents or young adults (those ages 18 to 25)” following legalization. They also found no evidence of increased cannabis abuse or dependence by either young people or adults. States with largely unregulated medical programs were associated with increased self-reported use by adults age 26 and older, but states with stricter programs were not.

    The study’s findings are consistent with those of numerous other papers reporting no uptick in youth marijuana use or abuse following medical marijuana regulation, including those here, here, here, here, here, and here. The findings contradict those of a recent, widely publicized paper in JAMA Psychiatry which speculated that medical marijuana laws may increase the prevalence of cannabis use disorder among adults.

    An abstract of the study, “Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder,” is online here.

  • by Paul Armentano, NORML Deputy Director June 4, 2017

    Marijuana researchScientists have conducted over 140 controlled clinical trials since 1975 assessing the safety and efficacy of whole-plant cannabis or specific cannabinoids, according to a new literature review published in the journal Critical Reviews in Plant Sciences.

    A pair of German researchers identified 140 clinical trials involving an estimated 8,000 participants. Of these, the largest body of literature focused on the use of cannabis or cannabinoids in the treatment of chronic or neuropathic pain. Authors identified 35 controlled studies, involving 2,046 subjects, assessing the use of marijuana or cannabinoids in pain management. In January, the National Academy of Sciences acknowledged that “conclusive or substantial evidence” exists for cannabis’ efficacy in patients suffering from chronic pain.

    Cannabinoids have also been well studied as anti-emetic agents and as appetite stimulants. Researchers identified 43 trials evaluating marijuana or its components for these purposes, involving total 2,498 patients. They also identified an additional 14 trials examining the role of cannabis or cannabis-derived extracts in the treatment of multiple sclerosis.

    Researchers also identified several additional trials evaluating the use of cannabis or cannabinoids for Crohn’s disease, Tourette’s syndrome, Parkinson’s disease, glaucoma, epilepsy, and various other indications.

    A 2014 study published in the Journal of the American Medical Association reported that new drugs typically gain FDA approval on the basis of one or two pivotal clinical trials.

    Full text of the study, “Medicinal uses of marijuana and cannabinoids,” appears online here.

Page 8 of 88« First...678910...203040...Last »